Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse effects?

Autor(es)

Canales, Giancarlo De la Torre ^[1] ; Poluha, Rodrigo Lorenzi ^[1] ; Lora, Victor Munoz ^[2] ; Araujo Oliveira Ferreira, Dyna Mara ^[1] ; Stuginski-Barbosa, Juliana ^[1] ; Bonjardim, Leonardo Rigoldi ^[1] ; Del Bel Cury, Altair Antoninha ^[2] ; Rodrigues Conti, Paulo Cesar ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Bauru Sch Dent, Dept Prosthodont, Bauru Orofacial Pain Grp, Bauru, SP - Brazil

^[2] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Prosthodont, Piracicaba - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CLINICAL ORAL INVESTIGATIONS; v. 23, n. 9, p. 3411-3421, SEP 2019.
• Citações Web of Science: 0

Resumo

Objectives The objective of the study was to conduct a systematic review of literature assessing botulinum toxin type A (BoNT-A) safety and adverse effects in the treatment of myofascial pain (MFP) and trigeminal neuralgia (TN). Materials and methods The search for articles by two specific researchers involved the PubMed, EMBASE, Web of Science, and Scopus databases. Specific terms were used, and no publication time and language restrictions were applied. Clinical trials that investigated the effects of BoNT-A among participants with myofascial pain in masticatory muscles or trigeminal neuralgia were considered eligible for this systematic review. Data for each study were extracted and analyzed according to a PICO-like structured reading. Results The search strategy provided 436 citations. After analysis, 16 citations were included, seven for MFP and nine for TN. In all studies, BoNT-A was well tolerated and improved pain. The most common adverse effects were temporary regional weakness, tenderness over the injection sites, and minor discomfort during chewing. Most studies reported a spontaneous resolution of adverse effect. Conclusions It can be concluded that BoNT-A treatment is well tolerated, since minor adverse effects were the most frequently reported; however, it is recommended that future studies aim to assess the safety and possible adverse effects of multiples applications or high doses of this treatment. (AU)

• Processo FAPESP: 17/21674-0 - Comparação da eficácia da toxina botulínica tipo A em pacientes com dor orofacial crônica refratária, de acordo com diferentes perfis somatosensoriais
• Beneficiário: Giancarlo de La Torre Canales
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado